Unlike treatment with EGFR-specific and anaplastic lymphoma kinase (ALK)-specific tyrosine kinase inhibitors (TKIs) of advanced NSCLC patients with high levels of CRP, LDH in the serum and poor performance status were found not fit for treatment with nivolumab [78]. This evidence concerns the gene ALK and non-small cell lung carcinoma.